

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

Crl:NU-Foxn1^{nu}

RRID:IMSR_CRL:088

Type: Organism

Proper Citation

RRID:IMSR_CRL:088

Organism Information

URL: <http://www.criver.com/products-services/basic-research/find-a-model/nu-nu-nude-mouse>

Proper Citation: RRID:IMSR_CRL:088

Description: Mus musculus with name Crl:NU-Foxn1^{nu} from IMSR.

Species: Mus musculus

Notes: gene symbol note: ; outbred stock:

Catalog Number: CRL:088

Database: Charles River Laboratories

Database Abbreviation: CRL

Availability: live

Organism Name: Crl:NU-Foxn1^{nu}

Record Creation Time: 20250513T062409+0000

Record Last Update: 20260829T054749+0000

Ratings and Alerts

No rating or validation information has been found for Crl:NU-Foxn1^{nu}.

No alerts have been found for Crl:NU-Foxn1^{nu}.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: Charles River Laboratories

Usage and Citation Metrics

We found 241 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Starrett JH, et al. (2026) Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity. *Molecular cancer therapeutics*, 25(3), 408.

Zhou W, et al. (2026) Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers. *Cell chemical biology*, 33(6), 785.

Zhang S, et al. (2026) Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer. *Cell reports. Medicine*, 7(3), 102660.

Banerjee M, et al. (2026) FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response. *Cancer research*, 86(10), 2522.

Xia Z, et al. (2026) A GPX1-OSBPL8 axis mediates noncanonical in vivo ferroptosis and cancer growth suppression. *Cell*, 189(7), 1957.

Xu W, et al. (2025) Safety, Efficacy and Bio-Distribution Analysis of Exosomes Derived From Human Umbilical Cord Mesenchymal Stem Cells for Effective Treatment of Bronchopulmonary Dysplasia by Intranasal Administration in Mice Model. *International journal of nanomedicine*, 20, 2521.

Martín F, et al. (2025) Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer. *Cell death & disease*, 16(1), 194.

Jiang P, et al. (2025) Inactivation of necroptosis-promoting protein MLKL creates a therapeutic vulnerability in colorectal cancer cells. *Cell death & disease*, 16(1), 118.

Baltanás FC, et al. (2025) SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRASG12D inhibitor in KRAS LUAD. *Proceedings of the National Academy of Sciences of the United States of America*, 122(11), e2422943122.

D'arrigo P, et al. (2025) An oncolytic herpesvirus expressing a CXCR4 antagonist interferes with glioblastoma cells' stemness features and migration. *Molecular therapy. Oncology*, 33(4), 201083.

Jacob J, et al. (2025) Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer. *Cancer research*, 85(5), 973.

McCabe M, et al. (2025) Small molecule disruption of RAR α /NCoR1 interaction inhibits chaperone-mediated autophagy in cancer. *EMBO molecular medicine*, 17(7), 1716.

Wu C, et al. (2025) Targeting Pancreatic Cancer Cell Stemness by Blocking Fibronectin-Binding Integrins on Cancer-Associated Fibroblasts. *Cancer research communications*, 5(1), 195.

Guillen Magaña JN, et al. (2025) Schlafen 12 Modulation and Targeting in Acute Myeloid Leukemia. *Cancer research communications*, 5(11), 2012.

High PC, et al. (2025) Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models. *bioRxiv : the preprint server for biology*.

Campos AD, et al. (2025) A STAT3/integrin axis accelerates pancreatic cancer initiation and progression. *Cell reports*, 44(8), 116010.

High PC, et al. (2025) Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models. *Cell reports. Medicine*, 102363.

Migliozzi S, et al. (2025) Restraint of cancer cell plasticity by spatial homotypic clustering. *Cancer cell*.

Ahmad ST, et al. (2025) Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target. *Cancer cell*, 43(6), 1141.

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. *Cell reports. Medicine*, 6(11), 102446.